NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates

Impact · against what's priced in

NeoGenomics shows strong operational momentum with a significant beat in EPS and steady revenue growth. The results confirm a positive trend in profitability, though the modest revenue beat suggests growth is scaling linearly rather than exponentially.

NEO+0.40

No priced-in read yet

In context

The company delivered a substantial earnings beat of $0.07 per share against a $0.06 estimate and grew EPS by 133% year-over-year, indicating strong margin expansion.

Read from the article alone

• earnings surprise▲450%
• earnings▲3%
• healthcare
• fundamental analysis
• NEO
• biomedical
• genetics
• medical testing